Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAI Plus Pembrolizumab and Enfortumab Vedotin in Metastatic Urothelial Carcinoma
NCT07217496Phase 1Not yet recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2026
- Primary completion
- Jan 2028
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nogapendekin alfa inbakicept in urothelial carcinoma (UC), sponsored by ImmunityBio, Inc. Primary endpoints: Safety and tolerability of the treatment regimen and Progression-Free Survival at 12 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07217496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217496.